

# Karla Cs Queiroz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11278852/publications.pdf>

Version: 2024-02-01

8  
papers

844  
citations

1307594

7  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

2016  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. <i>Cell Metabolism</i> , 2018, 28, 866-880.e15.	16.2	154
2	Oncophosphosignaling Favors a Glycolytic Phenotype in Human Drug Resistant Leukemia. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3846-3854.	2.6	7
3	PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. <i>Scientific Reports</i> , 2015, 5, 14534.	3.3	40
4	Fatty acid carbon is essential for dNTP synthesis in endothelial cells. <i>Nature</i> , 2015, 520, 192-197.	27.8	466
5	Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. <i>Journal of Pathology</i> , 2014, 234, 398-409.	4.5	17
6	Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. <i>International Journal of Cancer</i> , 2014, 135, 2294-2304.	5.1	58
7	Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. <i>Drug Resistance Updates</i> , 2012, 15, 211-222.	14.4	24
8	mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e150-e153.	1.6	78